Basic research of microRNA-34 for cancer therapy

Abstract

Abstract: MicroRNA-34(miR-34) inhibits many target genes involved in multiple oncogenic signaling pathways. The broad activity of miR-34 includes induction of cell cycle arrest and apoptosis, inhibition of tumor stem cells and metastasis and the anti-chemoresistance. There are increasing evidence suggesting that miR-34 plays a crucial role in cancer diseases and may be a potential therapeutic target. This review summarizes the biological function and molecular mechanisms of the miR-34 family, pharmacologies in animal tumor models, and reveals the possibility of miR-34 replacement therapy for the clinical treatment of tumor.

Key words: MicroRNA-34, Tumor, Gene therapy

CLC Number:

LI Zheng, XIANG Kai-ming, PENG Shu-ping, LI Gui-yuan. Basic research of microRNA-34 for cancer therapy[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2014, 19(1): 67-73.

References

[1] Gerlinger M, Rowan AJ, Horswell S, et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing[J]. N Engl J Med, 2012, 366(10):883-892.
[2] Parsons DW, Jones S, Zhang X, et al. An integrated genomic analysis of human glioblastoma multiforme[J]. Science, 2008, 321(5897):1807-1812.
[3] Djuranovic S, Nahvi A, Green R. miRNA-mediated gene silencing by translational repression followed by mRNA deadenylation and decay[J]. Science, 2012, 336 (6078):237-240.
[4] Piao X, Zhang X, Wu L, et al. CCR4-NOT deadenylates mRNA associated with RNA-induced silencing complexes in human cells[J]. Mol Cell Biol, 2010, 30(6):1486-1494.
[5] Wen CJ, Fu LJ, Wu LD, et al. Development of microRNA-dependent control of cytochrome P450[J]. Acta Metallurgica Sinica, 2011, V16:1304-1308.
[6] Wiggins JF, Ruffino L, Kelnar K, et al. Development of a lung cancer therapeutic based on the tumor suppressor microRNA-34[J]. Cancer Res, 2010, 70(14):5923-5930.
[7] Wu WH, Hu CP. Role of microRNA-21 in cardiovascular diseases[J]. Acta Metallurgica Sinica, 2012, V17(6):709-714.
[8] He L, He X, Lim LP, et al. A microRNA component of the p53 tumour suppressor network[J]. Nature, 2007, 447 (7148):1130-1134.
[9] Hsu SD, Chu CH, Tsou AP, et al. miRNAMap 2.0: genomic maps of microRNAs in metazoan genomes[J]. Nucleic Acids Res, 2008, 36:D165-D169.
[10] Calin GA, Sevignani C, Dumitru CD, et al. Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers[J]. Proc Natl Acad Sci USA, 2004, 101(9):2999-3004.
[11] Lodygin D, Tarasov V, Epanchintsev A, et al. Inactivation of miR-34a by aberrant CpG methylation in multiple types of cancer[J]. Cell Cycle, 2008, 7(16):2591-2600.
[12] Lujambio A, Calin GA, Villanueva A, et al. A microRNA DNA methylation signature for human cancer metastasis[J]. Proc Natl Acad Sci USA, 2008, 105(35):13556-13561.
[13] Vogt M, Munding J, Gruner M, et al. Frequent concomitant inactivation of miR-34a and miR-34b/c by CpG methylation in colorectal, pancreatic, mammary, ovarian, urothelial, and renal cell carcinomas and soft tissue sarcomas[J]. Virchows Arch, 2011, 458(3):313-322.
[14] Sun F, Fu H, Liu Q, et al. Downregulation of CCND1 and CDK6 by miR-34a induces cell cycle arrest[J]. FEBS Lett, 2008, 582(10):1564-1568.
[15] Liu C, Kelnar K, Liu B, et al. The microRNA miR-34a inhibits prostate cancer stem cells and metastasis by directly repressing CD44[J]. Nature medicine, 2011, 17(2):211-215.
[16] Ji Q, Hao X, Zhang M, et al. MicroRNA miR-34 inhibits human pancreatic cancer tumor-initiating cells[J]. PLoS One, 2009, 4(8):e6816.
[17] Chang TC, Wentzel EA, Kent OA, et al. Transactivation of miR-34a by p53 broadly influences gene expression and promotes apoptosis[J]. Mol Cell, 2007, 26(5):745-752.
[18] Tazawa H, Tsuchiya N, Izumiya M, et al. Tumor-suppressive miR-34a induces senescence-like growth arrest through modulation of the E2F pathway in human colon cancer cells[J]. Proc Natl Acad Sci USA, 2007, 104(39):15472-15477.
[19] Li N, Fu H, Tie Y, et al. miR-34a inhibits migration and invasion by down-regulation of c-Met expression in human hepatocellular carcinoma cells[J]. Cancer Lett, 2009, 275(1):44-53.
[20] Greenberg E, Hershkovitz L, Itzhaki O, et al. Regulation of cancer aggressive features in melanoma cells by microRNAs[J]. PLoS One, 2011, 6(4):e18936.
[21] Yan K, Gao J, Yang T, et al. MicroRNA-34a inhibits the proliferation and metastasis of osteosarcoma cells both in vitro and in vivo[J]. PLoS One, 2012, 7(3):e33778.
[22] Corney DC, Hwang CI, Matoso A, et al. Frequent downregulation of miR-34 family in human ovarian cancers[J]. Clin Cancer Res, 2010, 16(4):1119-1128.
[23] Asslaber D, Pinon JD, Seyfried I, et al. microRNA-34a expression correlates with MDM2 SNP309 polymorphism and treatment-free survival in chronic lymphocytic leukemia[J]. Blood, 2010, 115(21):4191-4197.
[24] Craig VJ, Cogliatti SB, Imig J, et al. Myc-mediated repression of microRNA-34a promotes high-grade transformation of B-cell lymphoma by dysregulation of FoxP1[J]. Blood, 2011, 117(23):6227-6236.
[25] Kaller M, Liffers ST, Oeljeklaus S, et al. Genome-wide characterization of miR-34a induced changes in protein and mRNA expression by a combined pulsed SILAC and microarray analysis[J]. Mol Cell Proteomics, 2011, 10(8):M111.
[26] Selbach M, Schwanhausser B, Thierfelder N, et al. Widespread changes in protein synthesis induced by microRNAs[J]. Nature, 2008, 455(7209):58-63.
[27] Yamakuchi M, Ferlito M, Lowenstein CJ. miR-34a repression of SIRT1 regulates apoptosis[J]. Proc Natl Acad Sci USA, 2008, 105(36):13421-13426.
[28] Chen QR, Yu LR, Tsang P, et al. Systematic proteome analysis identifies transcription factor YY1 as a direct target of miR-34a[J]. J Proteome Res, 2010, 10(2):479-487.
[29] Sui G, Shi Y, Brignone C, et al. Yin Yang is a negative regulator of p53[J]. Cell, 2004, 117(7):859-872.
[30] Bommer GT, Gerin I, Feng Y, et al. p53-mediated activation of miRNA34 candidate tumor-suppressor genes[J]. Curr Biol, 2007, 17(15):1298-1307.
[31] Shen Z, Zhan G, Ye D, et al. MicroRNA-34a affects the occurrence of laryngeal squamous cell carcinoma by targeting the antiapoptotic gene survivin[J]. Med Oncol, 2012, 29(4):2473-2480.
[32] Christoffersen NR, Shalgi R, Frankel LB, et al. p53-independent upregulation of miR-34a during oncogene-induced senescence represses MYC[J]. Cell Death Differ, 2009, 17(2):236-245.
[33] Liu N, Landreh M, Cao K, et al. The microRNA miR-34 modulates ageing and neurodegeneration in Drosophila[J]. Nature, 2012, 482(7386):519-523.
[34] Maes OC, Sarojini H, Wang E. Stepwise up-regulation of microRNA expression levels from replicating to reversible and irreversible growth arrest states in WI-38 human fibroblasts[J]. J Cell Physiol, 2009, 221(1):109-119.
[35] Kumamoto K, Spillare EA, Fujita K, et al. Nutlin-3a activates p53 to both down-regulate inhibitor of growth 2 and up-regulate mir-34a, mir-34b, and mir-34c expression, and induce senescence[J]. Cancer Research, 2008, 68(9):3193-3203.
[36] Welch C, Chen Y, Stallings RL. MicroRNA-34a functions as a potential tumor suppressor by inducing apoptosis in neuroblastoma cells[J]. Oncogene, 2007, 26(34):5017-5022.
[37] Tivnan A, Tracey L, Buckley PG, et al. MicroRNA-34a is a potent tumor suppressor molecule in vivo in neuroblastoma[J]. BMC Cancer, 2011, 11:33.
[38] Ichimura A, Ruike Y, Terasawa K, et al. MicroRNA-34a inhibits cell proliferation by repressing mitogen-activated protein kinase kinase 1 during megakaryocytic differentiation of K562 cells[J]. Mol Pharmacol, 2010, 77(6):1016-1024.
[39] Silber J, Jacobsen A, Ozawa T, et al. miR-34a repression in proneural malignant gliomas upregulates expression of its target PDGFRA and promotes tumorigenesis[J]. PLoS One, 2012, 7(3):e33844.
[40] de Antonellis P, Medaglia C, Cusanelli E, et al. MiR-34a targeting of Notch ligand delta-like 1 impairs CD15+/CD133+ tumor-propagating cells and supports neural differentiation in medulloblastoma[J]. PLoS One, 2011, 6(9):e24584.
[41] Choi YJ, Lin CP, Ho JJ, et al. miR-34 miRNAs provide a barrier for somatic cell reprogramming[J]. Nat Cell Biol, 2011, 13(11):1353-1360.
[42] Hashimi ST, Fulcher JA, Chang MH, et al. MicroRNA profiling identifies miR-34a and miR-21 and their target genes JAG1 and WNT1 in the coordinate regulation of dendritic cell differentiation[J]. Blood, 2009, 114(2):404-414.
[43] Kim NH, Kim HS, Kim NG, et al. p53 and microRNA-34 are suppressors of canonical Wnt signaling[J]. Sci Signal, 2011, 4(197):ra71.
[44] Mudduluru G, Ceppi P, Kumarswamy R, et al. Regulation of Axl receptor tyrosine kinase expression by miR-34a and miR-199a/b in solid cancer[J]. Oncogene, 2011, 30(25):2888-2899.
[45] Ji Q, Hao X, Meng Y, et al. Restoration of tumor suppressor miR-34 inhibits human p53-mutant gastric cancer tumorspheres[J]. BMC Cancer, 2008, 8:266.
[46] Fujita Y, Kojima K, Hamada N, et al. Effects of miR-34a on cell growth and chemoresistance in prostate cancer PC3 cells[J]. Biochem Biophys Res Commun, 2008, 377(1):114-119.
[47] Kojima K, Fujita Y, Nozawa Y, et al. MiR-34a attenuates paclitaxel-resistance of hormone-refractory prostate cancer PC3 cells through direct and indirect mechanisms[J]. Prostate, 2010, 70(14):1501-1512.
[48] Akao Y, Noguchi S, Iio A, et al. Dysregulation of microRNA-34a expression causes drug-resistance to 5-FU in human colon cancer DLD-1 cells[J]. Cancer Lett, 2010, 300(2):197-204.
[49] Vinall RL, Ripoll AZ, Wang S, et al. MiR-34a chemosensitizes bladder cancer cells to cisplatin treatment regardless of p53-Rb pathway status[J]. Int J Cancer, 2011, 130(11):2526-2538.
[50] Weeraratne SD, Amani V, Neiss A, et al. miR-34a confers chemosensitivity through modulation of MAGE-A and p53 in medulloblastoma[J]. Neuro Oncology, 2010, 13(2):165-175.
[51] Kasinski AL, Slack FJ. miRNA-34 prevents cancer initiation and progression in a therapeutically resistant K-ras and p53-induced mouse model of lung adenocarcinoma[J]. Cancer Res, 72(21):5576-5587.
[52] Chen Y, Zhu X, Zhang X, et al. Nanoparticles modified with tumor-targeting scFv deliver siRNA and miRNA for cancer therapy[J]. Molecular Therapy, 2010, 18(9):1650-1656.
[53] Pramanik D, Campbell NR, Karikari C, et al. Restitution of tumor suppressor microRNAs using a systemic nanovector inhibits pancreatic cancer growth in mice[J]. Mol Cancer Ther, 2011, 10(8):1470-1480.
[54] Trang P, Wiggins JF, Daige CL, et al. Systemic delivery of tumor suppressor microRNA mimics using a neutral lipid emulsion inhibits lung tumors in mice[J]. Molecular Therapy, 2011, 19(6):1116-1122.
[55] Craig VJ, Tzankov A, Flori M, et al. Systemic microRNA-34a delivery induces apoptosis and abrogates growth of diffuse large B-cell lymphoma in vivo[J]. Leukemia, 2012, 26(11):2421-2424.
[56] Bader AG, Daige CL, Kelnar K, et al. Preclinical data of a microRNA-based therapy for hepatocellular carcinoma[C]. Annual AACR Conference Presentation, March 31-April 4, Chicago, IL, 2012.